Kidswell Bio Corporation (TYO:4584)

Japan · Delayed Price · Currency is JPY

148.00

-2.00 (-1.33%)

Aug 6, 2026, 12:30 PM JST

-44.98% (1Y)

Market Cap	7.45B -41.9%
Revenue (ttm)	6.59B +29.7%
Net Income	-413.00M
EPS	-8.46
Shares Out	49.64M
PE Ratio	n/a
Forward PE	7.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,500
Open	149.00
Previous Close	150.00
Day's Range	147.00 - 150.00
52-Week Range	125.00 - 363.00
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The com... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 32

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4584

Full Company Profile

Financial Performance

In fiscal year 2026, Kidswell Bio's revenue was 6.59 billion, an increase of 29.65% compared to the previous year's 5.08 billion. Losses were -413.00 million, 1866.7% more than in 2025.

Financial Statements